Seres Therapeutics (NASDAQ:MCRB) Downgraded to “Sell” at Zacks Investment Research

Seres Therapeutics (NASDAQ:MCRBGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, StockNews.com started coverage on shares of Seres Therapeutics in a report on Thursday, March 31st. They issued a “hold” rating for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.83.

Shares of MCRB stock opened at $4.84 on Wednesday. The company has a 50 day moving average of $6.68 and a 200-day moving average of $7.64. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.19. Seres Therapeutics has a 12-month low of $4.61 and a 12-month high of $25.06. The firm has a market cap of $445.35 million, a P/E ratio of -6.45 and a beta of 3.42.

Seres Therapeutics (NASDAQ:MCRBGet Rating) last released its quarterly earnings data on Tuesday, March 1st. The biotechnology company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.10). The business had revenue of $7.22 million during the quarter, compared to the consensus estimate of $19.48 million. Seres Therapeutics had a negative return on equity of 47.52% and a negative net margin of 45.25%. During the same period last year, the business posted ($0.18) earnings per share. As a group, equities analysts expect that Seres Therapeutics will post -2.05 EPS for the current year.

Several institutional investors have recently bought and sold shares of the company. DekaBank Deutsche Girozentrale raised its position in shares of Seres Therapeutics by 3.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 67,000 shares of the biotechnology company’s stock valued at $577,000 after buying an additional 2,000 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Seres Therapeutics by 2.1% during the 4th quarter. California State Teachers Retirement System now owns 96,007 shares of the biotechnology company’s stock valued at $800,000 after buying an additional 2,007 shares in the last quarter. Royal Bank of Canada raised its position in shares of Seres Therapeutics by 90.3% during the 2nd quarter. Royal Bank of Canada now owns 4,765 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 2,261 shares in the last quarter. Teacher Retirement System of Texas raised its position in shares of Seres Therapeutics by 23.0% during the 4th quarter. Teacher Retirement System of Texas now owns 13,562 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 2,536 shares in the last quarter. Finally, Credit Suisse AG raised its position in shares of Seres Therapeutics by 8.5% during the 3rd quarter. Credit Suisse AG now owns 46,454 shares of the biotechnology company’s stock valued at $323,000 after buying an additional 3,644 shares in the last quarter. Hedge funds and other institutional investors own 80.70% of the company’s stock.

About Seres Therapeutics (Get Rating)

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).

Read More

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.